Apyx Medical announces underwritten public stock offering

Apyx Medical Corporation (NASDAQ: APYX) announced it is commencing an underwritten public offering of common stock shares. The Clearwater, Florida-based surgical aesthetics company said the offering is subject to market conditions and provided no assurance regarding completion, timing, size or terms.

Lucid Capital Markets will serve as the sole book-running manager for the offering. The company will conduct the offering under a shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on November 22, 2022, and declared effective December 2, 2022.

Apyx Medical develops surgical aesthetics products including its Helium Plasma Platform Technology marketed as Renuvion and the AYON Body Contouring System for cosmetic surgery, and J-Plasma for hospital surgical markets. The company also manufactures products for other medical device companies through original equipment manufacturer agreements.

A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and made available on the agency's website. Copies may also be obtained by contacting Lucid Capital Markets at 570 Lexington Avenue, 40th Floor, New York, NY 10022.

The company stated the press release does not constitute an offer to sell securities or solicitation of an offer to buy, noting that sales would be unlawful in jurisdictions lacking proper registration or qualification under applicable securities laws.

You May Also Be Interested In

• RenovoRx regains Nasdaq minimum bid price compliance
• Andersen closes secondary offering of 4.9M shares at $44 each
• Singularity Future Technology closes $5M registered direct offering